MaxLinear (MXL) has had the highest return since April 1, 2026 by a mid-cap US stock, returning 405.6%.
| ASSET | % RETURN |
|---|---|
MaxLinear (MXL) | 405.63% |
Penguin Solutions (PENG) | 338.29% |
Iovance Biotherapeutics (IOVA) | 304.44% |
Abcellera Biologics (ABCL) | 257.93% |
CareDx (CDNA) | 255.41% |
AMC Entertainment (AMC) | 200% |
Sellas Life Sciences (SLS) | 175.52% |
Clover Health Investments (CLOV) | 174.71% |
Hinge Health (HNGE) | 168.77% |
Strive (ASST) | 168.51% |
GRAIL, LLC (GRAL) | 163.69% |
Xometry (XMTR) | 159.21% |
BlackBerry (BB) | 157.62% |
Gitlab (GTLB) | 155.4% |
Kodiak Sciences (KOD) | 149.52% |
Maravai Lifesciences Holdings (MRVI) | 148.59% |
Insight Enterprises (NSIT) | 147.43% |
Pulse Biosciences (PLSE) | 138.84% |
Netskope, Inc Class A Common Stock (NTSK) | 137.51% |
Tenable (TENB) | 137.45% |
Five9 (FIVN) | 132.83% |
Organon (OGN) | 131.34% |
Amplitude (AMPL) | 125.07% |
Schrodinger (SDGR) | 124.72% |
Qualys (QLYS) | 122.29% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.